Abrdn Life Sciences Investors

Chris Lavictoire Mahai, a Director of abrdn Life Sciences Investors, purchased 527 shares of common stock on July 16, 2026 for $19.92 per share.

abrdn Life Sciences Investors Director Christian Pittard reported a planned purchase of 7,923 common stock shares at $16.8818, scheduled for December 16, 2025, under a Rule 10b5-1 plan.

Saba Capital Management, a 10% owner of abrdn Life Sciences Investors, reported sales of common stock totaling 48,612 shares.

Saba Capital Management, L.P., a 10% owner of abrdn Life Sciences Investors, reported the sale of 64,536 shares of common stock in mid-September 2025.

Saba Capital Management, a 10% owner and director, reported sales of abrdn Life Sciences Investors common stock totaling 2,726 shares in mid-September 2025.

Saba Capital Management, a 10% owner and director of abrdn Life Sciences Investors (HQL), reported selling 15,116 shares of common stock.

Abrdn Healthcare Investors, Abrdn Life Sciences Investors, Abrdn Healthcare Opportunities Fund, and Abrdn World Healthcare Fund have issued a joint proxy statement detailing their upcoming annual shareholder meetings on May 27, 2026, primarily for the election of Trustees.

Abrdn Healthcare Investors, abrdn Life Sciences Investors, abrdn Healthcare Opportunities Fund, and abrdn World Healthcare Fund will hold annual shareholder meetings on May 28, 2025, to elect trustees.

abrdn Life Sciences Investors (formerly Tekla Life Sciences Investors) is reaching out to shareholders to request their input on important operating initiatives.

abrdn Life Sciences Investors (HQL) will hold its annual shareholder meeting on June 25, 2024, to vote on the election of two Class B Trustees and a shareholder proposal regarding the annual election of all trustees.

Saba Capital Management, L.P. and affiliates reported a reduction in their beneficial ownership of abrdn Life Sciences Investors to 4.95% through open market sales.

Saba Capital Management, L.P. and affiliates have reduced their beneficial ownership in abrdn Life Sciences Investors, selling shares between January and February 2026.

Saba Capital Management, L.P. has reduced its beneficial ownership in abrdn Life Sciences Investors to 6.77% through open market sales.

Saba Capital Management, L.P. and its affiliates have amended their beneficial ownership in abrdn Life Sciences Investors to 7.88% of common shares, reporting recent open market transactions.

Saba Capital Management, L.P. has filed an amended Schedule 13D, disclosing a reduction in its beneficial ownership of abrdn Life Sciences Investors to 8.96% through recent open market sales.

Saba Capital Management, L.P. has filed an Amendment No. 7 to its Schedule 13D, reporting a 10.33% beneficial ownership in abrdn Life Sciences Investors after recent share sales.

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation jointly reported a 10.09% beneficial ownership stake in abrdn Life Sciences Investors.

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly disclosed a 6.33% beneficial ownership stake in abrdn Life Sciences Investors, totaling 1,827,112 common shares.